Eiger

EIGR NASDAQ
10.77
-0.43
-3.84%
After Hours: 10.77 0 0.00% 17:04 07/19 EDT
Open
11.16
Prev Close
11.20
High
11.26
Low
10.75
Volume
91.38K
Avg Vol (3M)
266.26K
52 Week High
15.33
52 Week Low
8.40
% Turnover
0.37%
Market Cap
263.17M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Eiger EIGR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
MORE >

Recently

Name
Price
%Change